Kisa, Renata M. - Resultados de la búsqueda - Depósito Digital de Documentos de la UAB

Buscar colecciones:

Ordenar por:	Mostrar resultados:	Formato de visualización:

Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros

Artículos	Encontrados 1 registros

16 p, 1.2 MB

Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial / Thaçi, Diamant (University of Luebeck) ; Strober, Bruce (Yale University) ; Gordon, Kenneth B. (Medical College of Wisconsin) ; Foley, Peter (The University of Melbourne) ; Gooderham, Melinda (Queen's University and Probity Medical Research) ; Morita, Akimichi (Nagoya City University) ; Papp, Kim A. (Clinical Research and Probity Medical Research) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Menter, M. Alan (Baylor University Medical Center) ; Colombo, Matthew J. (Bristol Myers Squibb) ; Elbez, Yedid (Bristol Myers Squibb) ; Kisa, Renata M. (Bristol Myers Squibb) ; Ye, June (Bristol Myers Squibb) ; Napoli, Andrew A. (Bristol Myers Squibb) ; Wei, Lan (Bristol Myers Squibb) ; Banerjee, Subhashis (Bristol Myers Squibb) ; Merola, Joseph F. (Harvard Medical School) ; Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai) ; Universitat Autònoma de Barcelona
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. [...]
2022 - DOI (Digital Object Identifier)

10.1007/s13555-021-00649-y
Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.